Dihydroquinidine versus disopyramide: Efficacy in patients with chronic stable ventricular ectopy

Chimienti, M; Panciroli, C; Ja, Salerno; Regazzi-Bonora, Mario; Previtali, Mario; Cristiani, D.; Rondanelli, R; Bobba, P

doi:10.1002/clc.4960071005

Cited by 7 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical usefulness of DQ in patients with ventricular arrhythmias, in the absence of ischemic heart disease, has been recently demonstrated in a controlled study in which DQ had a greater suppressive effect on PVB's than disopyramide [5]. Recently L~vy et al [6] have shown the drug to be highly effective in preventing recurrences of ventricular tachycardia in patients with previous myocardial infarction.…”

Section: Comparison Of Dq and Q Effectivenessmentioning

confidence: 99%

Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration

Chimienti

Regazzi

Rovere

et al. 1988

Cardiovasc Drug Ther

View full text Add to dashboard Cite

The aim of this study was to compare the pharmacokinetics and antiarrhythmic activity of dihydroquinidine and quinidine in 14 patients (11 men, 3 women, aged 28 to 67 years) with heart disease and chronic, stable, high-frequency premature ventricular beats (PVB) (greater than 100/hr). A randomized, double-blind, crossover, placebo-controlled protocol was utilized. During Holter monitoring the patients were given either dihydroquinidine or quinidine as the gluconates in an oral solution (600 mg); blood samples were taken 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours later. The patients were then assigned to three successive treatment periods of 7 days each: dihydroquinidine HCl (900 mg/day), quinidine polygalacturonate (1,650 mg/day), or placebo. At the end of each period 24-hour Holter monitoring was carried out and a blood sample was taken for determination of drug concentration. By comparing the area under the curves dihydroquinidine was 59% as available as quinidine; rates of absorption and elimination were similar. Mean peak blood levels of dihydroquinidine and quinidine were 1.06 +/- 0.34 and 2.15 +/- 0.96 micrograms/ml, respectively. After dihydroquinidine, eight patients had a positive response (greater than 50% reduction in PVB frequency), while seven patients responded to quinidine. During maintenance treatment both dihydroquinidine (233 +/- 330) and quinidine (234 +/- 311) reduced the mean PVB frequency per hour compared to placebo (690 +/- 569). Nine patients (64%) on dihydroquinidine and eight (57%) on quinidine had greater than 70% decrease in mean PVB frequency per hour. Steady-state peak plasma concentrations of dihydroquinidine and quinidine were 1.10 +/- 0.41 and 2.24 +/- 1.13 micrograms/ml, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Section: Comparison Of Dq and Q Effectivenessmentioning

confidence: 99%

Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration

Chimienti

Regazzi

Rovere

et al. 1988

Cardiovasc Drug Ther

View full text Add to dashboard Cite

show abstract

Comparison of Sustained‐Release Quinidines Given Twice Daily to Patients With Ventricular Ectopy

Lehmann

Boran

Kruyer

et al. 1986

The Journal of Clinical Pharma

View full text Add to dashboard Cite

To compare the steady-state kinetic profiles and ectopy-suppression rates of two sustained-release forms of quinidine with those of a conventional quinidine preparation, 18 patients with ventricular ectopy were studied in randomized crossover fashion. The drugs were conventional quinidine sulfate 300 mg q6h, sustained-release quinidine sulfate 600 mg q12h, and sustained-release quinidine gluconate 648 mg q12h. Following baseline electrocardiographic ambulatory monitoring, each drug was given for three days, with repeat ambulatory monitoring and serial plasma drug level determinations performed on the third day. There were no washout periods between treatments. Plasma quinidine levels were assayed by both enzyme multiplied immunoassay technique (EMIT) and quinidine-specific high-performance liquid chromatography (HPLC) methods. Using actual steady-state HPLC values, there were no differences in the area under the plasma concentration-time curve (AUC) among the three treatments; the dose-corrected AUC was greater for quinidine gluconate than for the other two preparations. Using EMIT values, mean plasma quinidine levels from the conventional quinidine sulfate regimen were greater during the last five hours of the 12-hour study interval. A consistently strong inverse relationship between EMIT plasma quinidine levels and hourly ectopy rates was present in only one of eight (13%) responders. Diurnal variation of quinidine kinetics was observed after two days of each treatment; trough values at midnight were slightly lower than trough values at noon. Among patients demonstrating at least 70% suppression of premature ventricular contractions (PVCs), there were no differences in ectopy rates or ectopy-suppression rates among treatments. Dosing sustained-release quinidine sulfate 600 mg or quinidine gluconate 648 mg q12h was clinically acceptable in the small number of responders studied.

show abstract

Prophylaxis of Atrial Fibrillation: What are the Benefits and Risks of the Different Antiarrhythmic Drugs?

Chimienti

Barbieri

1996

Cardiac Arrhythmias 1995

View full text Add to dashboard Cite

Dihydroquinidine versus disopyramide: Efficacy in patients with chronic stable ventricular ectopy

Cited by 7 publications

References 22 publications

Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration

Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration

Comparison of Sustained‐Release Quinidines Given Twice Daily to Patients With Ventricular Ectopy

Prophylaxis of Atrial Fibrillation: What are the Benefits and Risks of the Different Antiarrhythmic Drugs?

Contact Info

Product

Resources

About